Reports: Chinese firm to spend $315M on Ebola vaccine manufacturing plant

Despite the ebbing of the Ebola epidemic in West Africa, a Chinese firm says it will invest $315 million into a facility in Tianjin to mass produce an Ebola vaccine developed by a group out of China's Academy of Military Medical Sciences, Reuters reports. The facility, being built by Tianjin CanSino Biotechnology, will be finished between 2017 and 2018, the news service adds. Last December, the Chinese government approved the experimental vaccine for trials in an effort to compete with global leaders in the Ebola vaccine development space. More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.